Pharmacokinetics of doxorubicin in pregnant women.

MedStar author(s):
Citation: Cancer Chemotherapy & Pharmacology. 73(4):789-97, 2014 Apr.PMID: 24531558Institution: MedStar Health Research InstituteForm of publication: Journal ArticleMedline article type(s): Journal Article | Research Support, N.I.H., ExtramuralSubject headings: *Antibiotics, Antineoplastic/pk [Pharmacokinetics] | *Doxorubicin/pk [Pharmacokinetics] | *Neoplasms/dt [Drug Therapy] | *Neoplasms/me [Metabolism] | *Pregnancy Complications, Neoplastic/dt [Drug Therapy] | *Pregnancy Complications, Neoplastic/me [Metabolism] | Administration, Intravenous | Adult | Antibiotics, Antineoplastic/ad [Administration & Dosage] | Antibiotics, Antineoplastic/bl [Blood] | Antibiotics, Antineoplastic/ur [Urine] | Doxorubicin/ad [Administration & Dosage] | Doxorubicin/bl [Blood] | Doxorubicin/ur [Urine] | Female | Humans | Middle Aged | Neoplasms/bl [Blood] | Neoplasms/ur [Urine] | Pregnancy | Pregnancy Complications, Neoplastic/bl [Blood] | Pregnancy Complications, Neoplastic/ur [Urine] | Young AdultYear: 2014ISSN:
  • 0344-5704
Name of journal: Cancer chemotherapy and pharmacologyAbstract: CONCLUSIONS: In pregnant subjects, we observed significantly lower doxorubicin CL in our 72 h and most of our 48 h sampling comparisons with previously reported non-pregnant subjects. However, the parameters were within the range previously reported in smaller studies. At this time, we cannot recommend alternate dosage strategies for pregnant women. Further research is needed to understand the mechanism of doxorubicin pharmacokinetic 140821s during pregnancy and optimize care for pregnant women.METHODS: During mid- to late-pregnancy, serial blood and urine samples were collected over 72 h from seven women treated with doxorubicin for malignancies. PK parameters were estimated using non-compartmental techniques. Pregnancy parameters were compared to those previously reported non-pregnant subjects.PURPOSE: Our objective was to evaluate the pharmacokinetics (PK) of doxorubicin during pregnancy compared to previously published data from non-pregnant subjects.RESULTS: During pregnancy, mean (+SD) doxorubicin PK parameters utilizing 72 h sampling were: clearance (CL), 412 + 80 mL/min/m(2); steady-state volume of distribution (Vss), 1,132 + 476 L/m(2); and terminal half-life (T1/2), 40.3 + 8.9 h. The BSA-adjusted CL was significantly decreased (p < 0.01) and T1/2 was not different compared to non-pregnant women. Truncating our data to 48 h, PK parameters were: CL, 499 + 116 ml/min/m(2); Vss, 843 + 391 L/m(2); and T1/2, 24.8 + 5.9 h. The BSA-adjusted CL in pregnancy compared to non-pregnant data was significantly decreased in 2 of 3 non-pregnant studies (p < 0.05, < 0.05, NS). Vss and T1/2 were not significantly different.All authors: Akbarzadeh A, Berg SL, Easterling TR, Eyal S, Feldman EM, Hays K, Hebert MF, Kaplan HG, Miodovnik M, Puhl K, Ryu RJ, Scorsone KA, Umans JGFiscal year: FY2014Digital Object Identifier: Date added to catalog: 2014-08-21
Holdings
Item type Current library Collection Call number Status Date due Barcode
Journal Article MedStar Authors Catalog Article 24531558 Available 24531558

CONCLUSIONS: In pregnant subjects, we observed significantly lower doxorubicin CL in our 72 h and most of our 48 h sampling comparisons with previously reported non-pregnant subjects. However, the parameters were within the range previously reported in smaller studies. At this time, we cannot recommend alternate dosage strategies for pregnant women. Further research is needed to understand the mechanism of doxorubicin pharmacokinetic 140821s during pregnancy and optimize care for pregnant women.

METHODS: During mid- to late-pregnancy, serial blood and urine samples were collected over 72 h from seven women treated with doxorubicin for malignancies. PK parameters were estimated using non-compartmental techniques. Pregnancy parameters were compared to those previously reported non-pregnant subjects.

PURPOSE: Our objective was to evaluate the pharmacokinetics (PK) of doxorubicin during pregnancy compared to previously published data from non-pregnant subjects.

RESULTS: During pregnancy, mean (+SD) doxorubicin PK parameters utilizing 72 h sampling were: clearance (CL), 412 + 80 mL/min/m(2); steady-state volume of distribution (Vss), 1,132 + 476 L/m(2); and terminal half-life (T1/2), 40.3 + 8.9 h. The BSA-adjusted CL was significantly decreased (p < 0.01) and T1/2 was not different compared to non-pregnant women. Truncating our data to 48 h, PK parameters were: CL, 499 + 116 ml/min/m(2); Vss, 843 + 391 L/m(2); and T1/2, 24.8 + 5.9 h. The BSA-adjusted CL in pregnancy compared to non-pregnant data was significantly decreased in 2 of 3 non-pregnant studies (p < 0.05, < 0.05, NS). Vss and T1/2 were not significantly different.

English

Powered by Koha